- Cowen 39th Annual Health Care Conference on Tuesday, March 12, 2019 at 11:20 a.m. ET in Boston; and,
- Oppenheimer & Co. 29th Annual Healthcare Conference at 11:00 a.m. ET on March 20, 2019 in New York City.
Live webcasts will be available in the investor section of the company's website at www.epizyme.com. The webcasts also will be archived for 60 days following the call and presentation.
About Epizyme, Inc.
Epizyme, Inc. is a clinical-stage biopharmaceutical company committed to rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. Epizyme is broadly developing its lead product candidate, tazemetostat, a first-in-class EZH2 inhibitor, with studies underway in both solid tumors and hematological malignancies, as a monotherapy and combination therapy in relapsed and front-line disease. The company also is developing a novel G9a program with its next development candidate, EZM8266, which is targeting sickle cell disease. By focusing on the genetic drivers of disease, Epizyme's science seeks to match targeted medicines with the patients who need them. For more information, visit www.epizyme.com.
Erin Graves, (617) 500-0615